Division of Endocrinology, Diabetes and Metabolism, State University of New York and Kaleida Health, Buffalo, New York 14209, USA.
Endocr Pract. 2012 Mar-Apr;18(2):140-5. doi: 10.4158/EP11169.OR.
To assess whether liraglutide, a glucagon-like peptide-1 receptor agonist, has cardioprotective properties in addition to its glycemic effects.
We performed a retrospective analysis of medical records of 110 obese patients with type 2 diabetes mellitus treated with liraglutide for at least 6 months between March 2010 and April 2011 at our tertiary care referral center. The variables analyzed were body mass index, hemoglobin A(1c) (A1C), systolic blood pressure (SBP), plasma C-reactive protein (CRP) concentrations, and serum lipids.
In our overall study cohort, we noted a reduction in mean weight from 120 ± 5 kg to 115 ± 3 kg and a decrease in mean A1C from 7.8% ± 0.6% to 7.2% ± 0.2%. The mean triglyceride concentration decreased from 173 ± 19 mg/dL to 151 ± 15 mg/dL, the mean SBP was reduced from 132 ± 6 mm Hg to 125 ± 4 mm Hg, and the mean CRP concentration declined from 4.7 ± 0.8 mg/L to 3.2 ± 0.4 mg/L after treatment with liraglutide for a minimal duration of 6 months and a mean duration of 7.5 months (for all the foregoing changes, P<.05). These variables decreased whether these patients were previously treated with orally administered hypoglycemic agents alone or in combination with insulin or exenatide.
Our findings in a clinical practice show that liraglutide is a potent antidiabetes drug, whether given in combination with orally administered agents or insulin or as a substitution for exenatide. It lowers body weight, A1C levels, SBP, and CRP and triglyceride concentrations.
评估胰高血糖素样肽-1 受体激动剂利拉鲁肽除了具有降血糖作用外是否还有心脏保护作用。
我们对 2010 年 3 月至 2011 年 4 月在我们的三级转诊中心接受至少 6 个月利拉鲁肽治疗的 110 例肥胖 2 型糖尿病患者的病历进行了回顾性分析。分析的变量包括体重指数、糖化血红蛋白（A1C）、收缩压（SBP）、血浆 C 反应蛋白（CRP）浓度和血清脂质。
在我们的总体研究队列中，我们注意到平均体重从 120 ± 5kg 降至 115 ± 3kg，平均 A1C 从 7.8% ± 0.6%降至 7.2% ± 0.2%。平均甘油三酯浓度从 173 ± 19mg/dL 降至 151 ± 15mg/dL，平均 SBP 从 132 ± 6mmHg 降至 125 ± 4mmHg，平均 CRP 浓度从 4.7 ± 0.8mg/L 降至 3.2 ± 0.4mg/L，在接受利拉鲁肽治疗 6 个月后，平均持续时间为 7.5 个月（所有上述变化，P<.05）。这些变化发生在这些患者之前单独使用口服降糖药或联合胰岛素或艾塞那肽治疗或之前接受过这些治疗的情况下。
我们在临床实践中的发现表明，利拉鲁肽是一种有效的抗糖尿病药物，无论是与口服药物联合使用还是与胰岛素联合使用，还是作为艾塞那肽的替代品。它可降低体重、A1C 水平、SBP 和 CRP 及甘油三酯浓度。
